Silibinin improves hepatic and myocardial injury in mice with nonalcoholic steatohepatitis.

[1]  G. Musso,et al.  Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity , 2011, Annals of medicine.

[2]  E. Bugianesi,et al.  Nonalcoholic fatty liver disease: the hepatic trigger of the metabolic syndrome. , 2010, Journal of hepatology.

[3]  G. Li Volti,et al.  Treating fatty liver for the prevention of cardiovascular diseases , 2010, Hepatology.

[4]  N. Khaper,et al.  Targeting the vicious inflammation-oxidative stress cycle for the management of heart failure. , 2010, Antioxidants & redox signaling.

[5]  O. Tawfik,et al.  Monocyte chemoattractant protein-1-deficiency does not affect steatosis or inflammation in livers of mice fed a methionine-choline-deficient diet , 2010, Laboratory Investigation.

[6]  Udo Hoffmann,et al.  Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: The Framingham heart study , 2010, Hepatology.

[7]  B. Neuschwander‐Tetri,et al.  Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. , 2010, The New England journal of medicine.

[8]  R. Rector,et al.  Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model. , 2010, Journal of hepatology.

[9]  Petra C. Kienesberger,et al.  Shedding light on the enigma of myocardial lipotoxicity: the involvement of known and putative regulators of fatty acid storage and mobilization. , 2010, American journal of physiology. Endocrinology and metabolism.

[10]  J. Fernandez-Checa,et al.  Specific Contribution of Methionine and Choline in Nutritional Nonalcoholic Steatohepatitis , 2010, The Journal of Biological Chemistry.

[11]  M. Trauner,et al.  Fatty liver and lipotoxicity. , 2010, Biochimica et biophysica acta.

[12]  F. Bellanti,et al.  A Silybin-Phospholipid Complex Prevents Mitochondrial Dysfunction in a Rodent Model of Nonalcoholic Steatohepatitis , 2010, Journal of Pharmacology and Experimental Therapeutics.

[13]  K. Mellor,et al.  Reactive oxygen species and insulin‐resistant cardiomyopathy , 2010, Clinical and experimental pharmacology & physiology.

[14]  J. Muntané,et al.  Interleukin-6 is associated with liver lipid homeostasis but not with cell death in experimental hepatic steatosis , 2009, Innate immunity.

[15]  E. Brunt.  Histopathology of non-alcoholic fatty liver disease. , 2009, Clinics in liver disease.

[16]  B. S. Mohammed,et al.  Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity , 2009, Proceedings of the National Academy of Sciences.

[17]  N. Kaplowitz,et al.  Redox regulation of tumor necrosis factor signaling. , 2009, Antioxidants & redox signaling.

[18]  F. Marra,et al.  Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells. , 2009, Journal of hepatology.

[19]  R. Rodrigo,et al.  Liver NF‐κB and AP‐1 DNA Binding in Obese Patients , 2009, Obesity.

[20]  P. Ferenci,et al.  Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. , 2008, Gastroenterology.

[21]  James E. Nelson,et al.  Silybin Treatment is Associated With Reduction in Serum Ferritin in Patients With Chronic Hepatitis C , 2008, Journal of clinical gastroenterology.

[22]  B. S. Mohammed,et al.  Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. , 2008, Gastroenterology.

[23]  R. Green,et al.  Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet , 2008 .

[24]  F. Marra.  Nuclear factor-κB inhibition and non-alcoholic steatohepatitis: inflammation as a target for therapy , 2008, Gut.

[25]  S. Mantena,et al.  Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases. , 2008, Free radical biology & medicine.

[26]  J. Sastre,et al.  Uncoupling protein-2 (UCP2) induces mitochondrial proton leak and increases susceptibility of non-alcoholic steatohepatitis (NASH) liver to ischaemia–reperfusion injury , 2008, Gut.

[27]  R. Rector,et al.  Nonalcoholic fatty liver disease and mitochondrial dysfunction. , 2008, World journal of gastroenterology.

[28]  P. Scifo,et al.  Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver , 2007, Hepatology.

[29]  Stefan Neubauer,et al.  The failing heart--an engine out of fuel. , 2007, The New England journal of medicine.

[30]  A. Bonen,et al.  Effect of IL-6 deficiency on myocardial expression of fatty acid transporters and intracellular lipid deposits. , 2007, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[31]  B. Pedersen,et al.  The role of IL-6 in mediating the anti-inflammatory effects of exercise. , 2006, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[32]  F. Colina,et al.  Uric acid and anti‐TNF antibody improve mitochondrial dysfunction in ob/ob mice , 2006, Hepatology.

[33]  G. Svegliati-Baroni,et al.  A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury. , 2006, The American journal of pathology.

[34]  I. de Sio,et al.  A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observations , 2006, Gut.

[35]  J. McGavock,et al.  Adiposity of the Heart*, Revisited , 2006, Annals of Internal Medicine.

[36]  T. Lehtimäki,et al.  Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes. , 2006, American journal of physiology. Endocrinology and metabolism.

[37]  P. Kidd,et al.  A review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybin-phosphatidylcholine complex (Siliphos). , 2005, Alternative medicine review : a journal of clinical therapeutic.

[38]  R. Green,et al.  Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. , 2004, American journal of physiology. Gastrointestinal and liver physiology.

[39]  Zhigang Tian,et al.  Interleukin 6 alleviates hepatic steatosis and ischemia/reperfusion injury in mice with fatty liver disease , 2004, Hepatology.

[40]  B. Halliwell,et al.  Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean? , 2004, British journal of pharmacology.

[41]  R. Rodrigo,et al.  Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. , 2004, Clinical science.

[42]  A. Vollmar,et al.  Silibinin protects mice from T cell-dependent liver injury. , 2003, Journal of hepatology.

[43]  S. Seki,et al.  In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. , 2002, Journal of hepatology.

[44]  A. Mottino,et al.  Beneficial effects of silymarin on estrogen‐induced cholestasis in the rat: A study in vivo and in isolated hepatocyte couplets , 2001, Hepatology.

[45]  H. de Groot,et al.  Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin , 1996, Hepatology.

[46]  D. Ceccarelli,et al.  Antioxidant activity of silybin in vivo during long-term iron overload in rats. , 1995, Gastroenterology.

[47]  L. Mira,et al.  Scavenging of reactive oxygen species by silibinin dihemisuccinate. , 1994, Biochemical pharmacology.

[48]  S. Milani,et al.  Curcumin limits the fibrogenic evolution of experimental steatohepatitis , 2010, Laboratory Investigation.